81_CD
Alliance_NN
UniChem_NN
Plc_NN
18_CD
IMPAIRMENT_NOMZ
TESTING_GER
OF_PIN
GOODWILL_NN
AND_PHC
INTANGIBLE_NN
FIXED_VBD
ASSETS_NN
WITH_PIN
INDEFINITE_NN
LIVES_NN
CONTINUED_VBD
The_DT
net_JJ
book_NN
value_NN
of_PIN
retail_JJ
pharmacy_NN
licences_NN
by_PIN
these_DEMO
segments_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
million_CD
million_CD
UK_NN
579.7_CD
486.6_CD
The_DT
Netherlands_NN
101.0_CD
103.8_CD
Other_JJ
75.5_CD
74.6_CD
Indefinite_JJ
lives_NN
756.2_CD
665.0_CD
Subject_NN
to_TO
amortisation_VB
25.5_CD
26.5_CD
781.7_CD
691.5_CD
Goodwill_NN
and_CC
retail_JJ
pharmacy_NN
licences_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
testing_GER
,_,
or_CC
more_EMPH
frequently_RB
if_COND
there_EX
are_VPRT
indications_NOMZ
of_PIN
impairment_NOMZ
._.
The_DT
recoverable_JJ
amounts_NN
of_PIN
the_DT
CGUs_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
from_PIN
value-in-use_JJ
calculations_NOMZ
which_WDT [WHSUB]
use_VPRT
amounts_NN
from_PIN
the_DT
approved_VBN
budgets_NN
and_PHC
plans_NN
._.
The_DT
discount_NN
rate_NN
applied_VBN [WZPAST]
to_PIN
the_DT
cash_NN
flow_NN
projections_NOMZ
was_VBD [BEMA]
8_CD
%_NN
2004_CD
8_CD
%_NN
._.
Average_JJ
growth_NN
rates_NN
used_VBN
to_TO
extrapolate_VB
cash_NN
flows_NN
beyond_IN
the_DT
approved_VBN
budget_NN
and_PHC
plan_NN
period_NN
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
with_PIN
reference_NN
to_PIN
the_DT
CGUs_NN
country_NN
of_PIN
operation_NOMZ
and_PHC
business_NOMZ
segment_NOMZ
,_,
and_ANDC
ranged_VBD
from_PIN
1_CD
%_NN
to_PIN
2_CD
%_NN
2004_CD
1_CD
%_NN
to_PIN
2_CD
%_NN
._.
The_DT
respective_JJ
growth_NN
rates_NN
did_VBD
not_XX0
exceed_VB
the_DT
average_JJ
long-term_JJ
growth_NN
rate_NN
for_PIN
the_DT
relevant_JJ
market_NN
._.
